Advanced Image Analysis for Personalized Cancer Care

Nucs AI provides advanced AI-driven solutions that deliver precise, actionable insights for the clinical management of prostate cancer, empowering healthcare professionals.

Nucs AI Products

Explore the future of prostate cancer care with Nucs AI

Radiologist reviewing a PSMA-PET/CT scan on a computer screen with a patient, showcasing advanced AI analysis for prostate cancer treatment.

Comprehensive Tumor Analysis

DeepPSMA

Fast and reproducible whole-body tumor burden quantification in PSMA-PET/CT imaging, delivering critical insights on tumor characteristics.

Request Demo

Personalized Treatment Predictions

SelectPSMA

AI-powered predictions of patient outcomes following treatment with PSMA-targeted radiopharmaceuticals, helping to avoid ineffective treatments and side effects.

Request Demo

How Nucs AI Works?

Nucs AI seamlessly integrates into clinical workflows in three simple steps

Computer screen displaying patient imaging data, demonstrating the secure upload process to Nucs AI’s advanced platform for privacy and confidentiality.

Step 1

Data Input

Upload patient imaging data securely to Nucs AI's advanced platform, ensuring complete privacy and confidentiality.

Digital representation of AI algorithms analyzing imaging data, illustrating the process of quantifying tumor burden and predicting patient outcomes on Nucs AI’s platform.

Step 2

AI Analysis

Our advanced AI algorithms analyze the imaging data to quantify tumor burden and predict patient outcomes.

Nucs AI DeepPSMA and SelectPSMA reports with detailed evidence-based data and insights, used for personalized patient care.

Step 3

Report Generation

Receive detailed, evidence-based reports that provide actionable insights for personalized patient care.

Key Features and Benefits

Discover the advanced features and significant benefits of Nucs AI

Infographic showing 54% of patients as non-responders to Pluvicto therapy, highlighting how SelectPSMA helps clinicians identify these patients to avoid ineffective treatments.

Advanced AI

Tailored Treatment Plans

46% of patients who receive Pluvicto therapy have a response. Using SelectPSMA clinicians can identify patients unlikely to benefit from Pluvicto and avoid futile treatments.

Precision Medicine

Personalized Cancer Care

The number of prostate cancer cases will double by 2024. Personalized cancer management using Nucs Al tools is more critical than ever.

Enhanced Clinic Workflow

Seamless Integration

Integrates smoothly into existing clinical workflows, improving efficiency and decision-making process for radiologists and clinicians.

Comparison of PSMA-PET/CT scan images before and after analysis with DeepPSMA, showing advanced image analysis that reveals cancer characteristics to guide evidence-based clinical decisions.

Evidence-Based Decisions

Reliable Data

Advanced image analysis of PSMA-PET/CT using DeepPSMA uncovers meaningful cancer characteristics to guide clinicians in making evidence-based decisions on patient management.

1 in 8

Adult males develop prostate cancer during their lifetime.

2x

Prostate cancer cases are predicted to double by 2024.

12%

Of prostate cancer patients have metastatic castration-resistant disease which is lethal.

54%

Of radiologists are affected by burnout. DeepPSMA is improving interpretation of PSMA PET/CT scans, decreasing radiologists’ workload.

56%

Patients who receive treatment with Pluvicto do not have a clinical benefit. SelectPSMA is improving patient selection for Pluvicto.

92%

Detection accuracy has PSMA-PET/CT imaging which creates opportunity for personalized medicine.

Contact us today

Take the next step to discover how Nucs AI can transform your clinical management of prostate cancer care.